Efficacy in Japanese adults with growth hormone deficiency receiving weekly somapacitan or daily growth hormone: results from phase 3 REAL 1 trial [PDF]
Frontiers in EndocrinologyIntroductionSomapacitan is a long-acting growth hormone (GH) derivative approved for once-weekly treatment of adult GH deficiency (AGHD). This study aimed to evaluate the efficacy and safety of somapacitan and daily GH in Japanese individuals with AGHD ...
Fumio Otsuka +5 more
doaj +2 more sources
Common polymorphisms of growth hormone: Growth hormone receptor axis in Turkish children with short stature [PDF]
, 2022 Objective: A single-nucleotide polymorphism of the growth hormone 1 gene, GH1IVS4+90A>T (rs2665802), associated with short stature and a polymorphism of the growth hormone receptor gene, exon 3 deleted variant, associated with increased responsiveness to
Adal, Servet Erdal +5 more
core +1 more source
Prolyl Endopeptidase-like Deficiency Associated with Growth Hormone Deficiency
JCRPE, 2023 Prolyl endopeptidase-like (PREPL) deficiency (MIM#616224) is a rare congenital disorder characterised by neonatal hypotonia and feeding difficulties, growth hormone (GH) deficiency and hypergonadotropic hypogonadism.
Laura Sayol-Torres +5 more
doaj +1 more source
Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: Summary statement of the growth hormone research society workshop on adult growth hormone deficiency [PDF]
, 1998 Based on the increasing body of evidence that adults with GH deficiency (somatotropin deficiency) have impaired health that improves with GH replacement, many countries have already approved the use of GH for replacement therapy in adults with GH ...
Clemmons, David +1 more
core +2 more sources
Idiopathic combined adrenocorticotropin and growth hormone deficiency mimicking chronic fatigue syndrome [PDF]
, 2021 A 42-year-old man who had suffered from severe fatigue for 5 years was diagnosed as having chronic fatigue syndrome (CFS) and fibromyalgia. Endocrinological workup using combined anterior pituitary function tests showed that the patient had ...
Ochi, Kanako +2 more
core +1 more source
Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH research society [PDF]
, 2000 The diagnosis and treatment of GH deficiency (GHD) during childhood and adolescence have been the subject of much controversy (1–3). To insure that patients are appropriately identified and treated, the GH Research Society (GRS) convened a workshop, on ...
Clemmons, David +1 more
core +2 more sources
Archives of Endocrinology and Metabolism, 2022 SUMMARY We present the unique case of an adult Brazilian woman with severe short stature due to growth hormone deficiency with a heterozygous G to T substitution in the donor splice site of intron 3 of the growth hormone 1 (GH1) gene (c.291+1G>T).
Julia Haddad Labello +8 more
doaj +1 more source
Short-term effect of growth hormone treatment in childhood leukemia survivors with growth hormone deficiency [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2022 Purpose Survivors of childhood leukemia are at risk of growth impairment due to intensive chemotherapy and radiation treatments. This study investigated the auxological and biochemical characteristics of childhood leukemia survivors diagnosed with growth
Chungwoo Shin +8 more
doaj +1 more source
Adult growth hormone deficiency [PDF]
Clinical Medicine, 2003 Growth hormone deficiency (GHD) in adults arises as a consequence of decreased secretion of somatotropin (GH) from the anterior pituitary. The diagnosis of GHD is dependent on the demonstration of a subnormal rise in serum GH in response to one or more dynamic stimulation tests in the presence of co-existing pituitary disease or other pituitary hormone
A M Brooke, John P. Monson
openaire +3 more sources
Do the Benefits of Growth Hormone Outweigh the Risks? [PDF]
, 2023 Growth hormone treatment was introduced in the 1950s to confront growth hormone deficiency and metabolic irregularities. In 2003, however, the FDA approved growth hormone treatment for patients with abnormal growth rates unlinked to growth hormone ...
Michael D. Goodstein
core +1 more source